|
Smarter use of generic, biosimilar and value added medicines will ensure equitable access to cancer care |
Medicines for Europe |
Thu, 02/04/2021 |
Health & Consumers |
|
SPC manufacturing waiver cannot be derailed by foreign vested interests |
Medicines for Europe |
Thu, 02/07/2019 |
Health & Consumers |
|
SPC manufacturing waiver moves a step closer as influential European Parliament ENVI Committee supports reform |
Medicines for Europe |
Tue, 09/18/2018 |
Health & Consumers |
|
SPC manufacturing waiver, Competition policy, Brexit, pharma incentives European Patent Office take centre stage at 14th Legal Affairs Conference |
Medicines for Europe |
Wed, 04/25/2018 |
Health & Consumers |
|
STADA’s Stephan Eder sets Access, Manufacturing and Sustainability at heart of Medicines for Europe Presidency |
Medicines for Europe |
Mon, 01/13/2025 |
InfoSociety |
|
Stronger mandate for European Medicines Agency should prioritise patient access to medicines |
Medicines for Europe |
Mon, 01/24/2022 |
Health & Consumers |
|
Supply chain commitment to tackling problem of medicine shortages |
Medicines for Europe |
Fri, 03/02/2018 |
Health & Consumers |
|
The EU must stop the offshoring of essential medicines manufacturing investments: ambitious, open and coherent policies must support competitive, robust and sustainable production of APIs and medicines |
Medicines for Europe |
Tue, 11/23/2021 |
Global Europe |
|
The European Commission needs to prioritise equitable access to biosimilar medicines in Europe |
Medicines for Europe |
Tue, 01/25/2022 |
Health & Consumers |
|
The European Medicines Verification System (EMVS) celebrates 1 year of successful operation across Europe |
Medicines for Europe |
Fri, 02/07/2020 |
Health & Consumers, InfoSociety |
|
The future EU health agenda should bring EU solidarity to life |
Medicines for Europe |
Tue, 03/26/2024 |
Health & Consumers |
|
The off-patent medicines industry is a vital part of the solution for healthcare resilience |
Medicines for Europe |
Thu, 06/30/2022 |
Health & Consumers |
|
Time for the EU to take steps: a medicines security act is needed for health security |
Medicines for Europe |
Mon, 10/02/2023 |
Health & Consumers |
|
Time to modernise the eu pharmaceutical regulatory framework to deliver on access |
Medicines for Europe |
Thu, 01/30/2020 |
Health & Consumers, InfoSociety |
|
US interference unacceptable in EU legislative proposal for an SPC manufacturing waiver |
Medicines for Europe |
Mon, 10/22/2018 |
Health & Consumers |
|
Value added medicines: Continuous innovation crucial to improve healthcare across Europe |
Medicines for Europe |
Wed, 11/21/2018 |
Health & Consumers |
|
Value Added Medicines: Time to adjust the HTA Decision Frameworks for more patient-centric innovation |
Medicines for Europe |
Tue, 09/05/2017 |
Health & Consumers |
|
Vigilance saves lives! More focus needed on sustainability and patient engagement |
Medicines for Europe |
Wed, 01/24/2018 |
Health & Consumers |
|
Vote to level up the European Health Union in upcoming elections |
Medicines for Europe |
Mon, 03/25/2024 |
Health & Consumers |
|
Window of opportunity to enhance EU regulatory systems wide open as EU pharma strategy prioritises stronger EU networks |
Medicines for Europe |
Tue, 01/19/2021 |
Health & Consumers |
|
‘Health revolution’: when smart innovation benefits patients |
Medicines for Europe |
Thu, 11/21/2019 |
Health & Consumers |
|
‘Together for Health’: Medicines for Europe launches election manifesto to deliver on equitable patient access |
Medicines for Europe |
Wed, 04/03/2019 |
Health & Consumers |
